INTERVIEW: Leaving construction to fight the industry's mental health crisis
It's suicide.
So what's fuelling it?
And what can you do if you or someone you know is struggling?
We've been unpacking the industry's hidden hazards with someone who's lived through them: Dr Simon Tyler, who now works as a psychologist helping to address the high rates of suicide within construction.
When we ran a shorter cut of this interview on the radio show, it had a huge response from people wanting to talk about it.
In this extended interview, Dr Tyler shares more of his insights and experiences, and also offers some advice.
And remember, Lifeline is there on 13 11 14.
Guest:
Dr Simon Tyler, psychologist and men's mental health researcher
Get the whole story from Hack:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
ABC News
13 minutes ago
- ABC News
Health minister expects blindsided states to match $2 billion funding pledge for Thriving Kids
The federal health minister expects the states and territories to match his $2 billion funding pledge aimed at moving children with mild to moderate developmental delays and autism off the National Disability Insurance Scheme, despite blindsiding them with the new program. Mark Butler on Wednesday used his first major speech since taking over the NDIS portfolio to outline the next stage of the scheme, including a tighter growth target of 5 or 6 per cent and a new Thriving Kids program. The program is the latest iteration of the federal government's efforts to establish so-called "foundational supports", a separate tier of services provided by the states through schools, childcare and health services for people with less profound disabilities. Two years ago, federal, state and territory leaders agreed to split $10 billion in funding for the program, imagined as a way to return the NDIS to it's original purpose of supporting Australians with profound and lifelong disabilities. Mr Butler on Wednesday made clear he expected the agreement would extend to the new children-focused program, as it covered one part of the original foundational supports plan and the funding is part of the initial $10 billion agreement. "I committed $2 billion on behalf of the Commonwealth yesterday over four years. The commitment by National Cabinet was that states would match that," he told 2GB. "Obviously not each of the states would do that, but collectively the states would put in $2 billion to that as well." But state and territory leaders stopped short of committing to a dollar figure a day after Mr Butler's speech, telling reporters they had not been consulted about the new program until it was announced. Victoria Premier Jacinta Allen said she was not told ahead of time, like "many states and territories", a sentiment echoed by the Western Australian and Queensland disability services ministers Hannah Beazley and Amanda Camm. "Today was the first time we'd heard about the minister's Thriving Kids program," Ms Camm said on Wednesday. "We look forward to continuing our work supporting the federal government given the NDIS is their responsibility." Meanwhile, New South Wales Premier Chris Minns told reporters he had been looped in ahead of time but without much warning. He said he would not "sign a blank cheque" for a program he didn't have the details of, but that he "will commit to working with the Commonwealth to have a sustainable disability support program". Ms Beazley said foundational supports was an "equally co-funded model" and she looked forward to continuing discussions, while Ms Allen urged the federal government to provide further details. "There are many families, particularly many parents, that have got many questions and I hope the federal government can move quickly to answer the many questions today," she said. Foundational supports was agreed to in 2023 and initially slated to begin by July 2025, but the rollout has been stalled and the services yet to be properly defined. The proposal focused on the provision of lower-level supports to be delivered outside the NDIS, in a bid to slow growth on the ballooning $46 billion scheme. Under the agreement, the federal and state governments would provide $10 billion in funding over five years, to be split equally along with any future costs. Mr Minns said he understood the need for an "updated plan". "They've looked at it and decided that having a different scheme in Queensland, New South Wales and Victoria is really uneven, particularly lumpy and probably not sustainable," he said. The health minister used a media tour on Wednesday to assure worried parents of children on the scheme that they would not slip through the cracks. "I want to reassure them that we're not going to leave them high and dry," he said. "We're going to make sure that there is a well-designed scheme that gives them confidence that we're going to do everything we can to support their kids to thrive."
ABC News
an hour ago
- ABC News
Next steps when someone shares they are experiencing domestic violence
When someone says they are experiencing domestic violence, you might feel unsure about how best to support them. "We find a lot of people get very uncomfortable with disclosure [about abuse], so they divert the conversation to something else," says Angie Gehle, senior policy and advocacy officer at Domestic Violence NSW. "That can inadvertently shut down the victim-survivor — it tells them they are not important, and they have chosen the wrong person to trust with that information." It takes "enormous courage" for a victim-survivor to disclose abuse, she says, and they will be considering many complexities when doing so, including their safety. Whether it's a family member, friend or colleague, it's helpful to understand how difficult disclosing experiences of domestic violence can be. As well as how to respond in the moment, and the best way to provide ongoing support. The most important thing you can do when someone says they are experiencing violence is to validate them, explains Alina Thomas, CEO at Engender Equality in Tasmania. "Giving some sort of reassurance and positive statement that you believe what the victim-survivor is saying, that what they said is significant. And that you care and worry about them." She says what you say will likely influence what steps they take next. "If they feel heard and believed and validated, it restores that little bit of self-worth and agency … which might help them see some options toward greater safety." Ms Gehle says when we get this wrong, such as by making statements that minimise the abuse, the person may shut down. Ms Thomas says it's good to ask questions to get a sense of what is going on, but be mindful to not push the person beyond what they are willing to share. If the person, their children or their pets are in immediate danger, you should contact triple-0. Ms Thomas says it is likely that victim-survivors have been working hard for a long time to keep their family together before disclosing. "Often, we really want the relationship to work, we put in a lot of effort and care, trying to problem-solve when things aren't going well. "When that isn't working, we can feel we are to blame." As well as experiencing shame, they may fear what will happen after confiding in someone, Ms Thomas says. "It's one reason we hold onto abusive relationships for so long. It's also why we don't want to see abuse. "Once you see abuse, you then need to think about it as a problem, and then solving it, then facing change." Ms Thomas says victim-survivors are also mindful of how their perpetrator is perceived by others, and worry people won't believe them. "You could be met with comments such as 'Oh no, he's a really nice guy', or 'If it's been that bad, why are you still with him?'" Women are nearly three times more likely than men to experience violence from an intimate partner in Australia. And statistics show men are more likely to be perpetrators. Victim-survivors may want to protect their abuser, too. "There are going to be positive attributes to their partner they want to support and for others to know about," says Ms Thomas. Victim-survivors will be considering so many factors when disclosing abuse. "She will be considering the perpetrator, her future, the risk to her safety — so many complex issues, and knowing providing information about what she is experiencing is incredibly risky," Ms Gehle says. "Especially if she is a mother, she is considering her children before anything else." When disclosing, the person may not always say directly they are experiencing domestic violence. Ms Gehle says some victim-survivors know something is wrong, but don't define it as abuse — especially when it's not physical — and are looking to sense check with you. Even if you identify it as abuse, she says it can be more helpful to simply validate what they are experiencing, rather than rushing to label it. "Sometimes by labelling something, the victim-survivor might disengage because it's so confronting," explains Ms Gehle. "It's better to have a narrative of, 'That sounds really hard, it sounds like you're being treated unfairly, and I don't think that's OK. Let's work out how I can best support you'." After listening and validating, discuss how you can best provide support. That will include working out a safe way to check in moving forward. "The person using abusive behaviour might have a lot of control and oversight of the victim-survivor — they might be monitoring their phone, emails, tracking where their car is going," says Ms Thomas. "We need to be careful that we are not contributing in any way to raising alarm bells." She says if a perpetrator finds out the victim-survivor has spoken to someone about the abuse, the violence could escalate. Suggesting they connect with specialist support services such as 1800RESPECT is a good starting point if safe to do so, says Ms Gehle. You can contact 1800RESPECT for advice and information as a support person, too. "They might also not be domestic violence specific, but [you can suggest] other potential supports like women's health services, community centres, or playgroups for women who have children — so their support system is growing slightly," Ms Gehle says. The most important thing is to remember victim-survivors are the expert on their own relationship and safety. Ms Thomas says you need to maintain their confidentiality. "Don't act on anything without telling them or asking them what you'd like to do. "Perhaps you think it's a good idea to go police, but you wouldn't do that unless they agreed. "And you wouldn't talk to the person using abusive behaviour without explicit consent." While you might be feeling protective, Ms Gehle agrees people should avoid "jumping in and being a saviour". "Sometimes friends and colleagues have a simplistic view on how to fix really complex issues," she says. Ms Thomas it can be tricky to be a support person, especially when you want to see immediate changes for them. "You have to keep in mind their life has been really taken over by the person using abuse. "They are probably feeing trapped, feeling reduced as a person within that situation. "I know that it can be hard as a support person when you think 'There should be a way through this', but it's not necessarily going to be obvious, or quick." She says you shouldn't encourage the person to leave without them having a safety plan and supports in place first. Leaving the relationship is the most dangerous time for a victim-survivor and it can take between seven and 10 times for them to leave permanently, says Ms Gehle. "It's really critical if you are going to be a supporter, that you remain that supporter … in all scenarios."
The Australian
2 hours ago
- The Australian
LTR Pharma's ED spray makes peer-reviewed journal
LTR Pharma's phase I pharmacokinetic study of nasal spray mist to treat erectile dysfunction published in leading peer-reviewed journal Publication validates five times faster onset, strengthening regulatory pathway and physician adoption LTR Pharma is targeting the US$3.7 billion ED market with SPONTAN and its other intranasal vardenafil formulation ROXUS Special Report: Results of LTR Pharma's phase I pharmacokinetic (PK) study of SPONTAN, its nasal spray mist to treat erectile dysfunction, have been published in the peer-reviewed European Journal of Pharmaceutical Sciences. The publication provides independent validation of SPONTAN – LTR Pharma's (ASX:LTP) lead intranasal vardenafil formulation for ED – including ultra-rapid onset, showing peak plasma concentrations in just 10 minutes compared with 45 minutes for conventional oral ED tablets. Mean Tmax values were 12 minutes for SPONTAN versus 56 minutes for tablets, confirming consistent rapid absorption across participants. Tmax refers to the time it takes for a drug to reach its maximum concentration (Cmax) in the bloodstream after administration. The European Journal of Pharmaceutical Sciences is a leading international peer-reviewed publication that highlights high-impact research in pharmaceutical sciences and drug delivery. Publication in the journal requires rigorous peer review by independent scientific experts and represents significant third-party validation of clinical data quality. LTR Pharma said publication in the journal adds substantial credibility to LTR's regulatory dossier as the company advances towards full commercialisation. "This peer-reviewed validation marks a transformative milestone for LTR Pharma. We now have independent scientific confirmation that our technology delivers what ED patients have been seeking for decades - true spontaneity,' executive chairman Lee Rodne said. About the PK study The randomised crossover study in 18 healthy male volunteers compared SPONTAN nasal spray (5 mg vardenafil) with oral vardenafil tablets (10 mg). Key clinical findings included: Ultra-rapid onset – SPONTAN reached peak plasma concentration (Tmax) in a median of 10 minutes versus 45 minutes for oral tablets, with mean values of 12 minutes versus 56 minutes respectively. Superior efficiency – Despite half the dose, SPONTAN achieved higher bioavailability per milligram, with dose-normalised Cmax of 2.58 ng/mL/mg versus 1.67 ng/mL/mg for oral administration. Comparable duration – Similar half-life of ~4 hours for both formulations, supporting sustained therapeutic effect. Manageable tolerability – Safety profile consistent with the PDE5 inhibitor class, with no serious adverse events reported. While the study specifically evaluated SPONTAN, the PK data support the company's broader intranasal delivery platform for vardenafil, which also includes ROXUS. Both products leverage the same rapid-onset technology, providing LTR with multiple commercial opportunities in different market segments from a single validated drug delivery platform. Targeting increased spontaneity Importantly, the publication notes that current oral PDE5 inhibitors face significant limitations, including delayed onset of 30 minutes to two hours, reduced efficacy with food intake, and the need for careful timing around sexual activity. These factors contribute to discontinuation rates of ~4% per month, with lack of spontaneity cited as a primary reason for treatment abandonment. The study authors concluded that 'intranasally delivered vardenafil is associated with more rapid onset of action with similar plasma concentrations'. They said that 'this differential pharmacokinetic profile has potentially important clinical implications given the overall safety and efficacy profile of PDE5 inhibitors in the treatment of ED, especially in men seeking sexual spontaneity'. Chief medical officer Professor Geoff Strange noted the peer-reviewed publication provided robust scientific validation of SPONTAN's 'game-changing pharmacokinetic profile'. 'The data clearly demonstrate that our intranasal delivery technology achieves the desired therapeutic levels in under 10 minutes – addressing the spontaneity challenge that drives part of the 50% of patients discontinuing oral ED treatments within their first year,' he said. 'From a clinical perspective, this represents a fundamental advancement in how PDE5 inhibitors can be administered, with the potential to significantly improve treatment adherence and patient satisfaction." SPONTAN is currently available in Australia through the Therapeutic Goods Administration Special Access Scheme, while it is targeting approval in other key markets. LTR Pharma is advancing a US Food and Drug Administration (FDA) regulatory submission via the 505(b)(2) pathway for SPONTAN approval with the US ED market valued at US$3.7 billion. The company said the journal publication strengthens its clinical evidence package for regulatory authorities. This article was developed in collaboration with LTR Pharma, a Stockhead advertiser at the time of publishing. This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.
